These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11991219)

  • 1. The role of spironolactone in the treatment of patients with refractory hypertension.
    Ouzan J; Pérault C; Lincoff AM; Carré E; Mertes M
    Am J Hypertens; 2002 Apr; 15(4 Pt 1):333-9. PubMed ID: 11991219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study.
    Ni X; Zhang J; Zhang P; Wu F; Xia M; Ying G; Chen J
    J Clin Hypertens (Greenwich); 2014 Sep; 16(9):658-63. PubMed ID: 25052724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of low-dose spironolactone in subjects with resistant hypertension.
    Nishizaka MK; Zaman MA; Calhoun DA
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):925-30. PubMed ID: 14573330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
    Václavík J; Sedlák R; Plachy M; Navrátil K; Plásek J; Jarkovsky J; Václavík T; Husár R; Kociánová E; Táborsky M
    Hypertension; 2011 Jun; 57(6):1069-75. PubMed ID: 21536989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of spironolactone therapy in patients with true resistant hypertension.
    de Souza F; Muxfeldt E; Fiszman R; Salles G
    Hypertension; 2010 Jan; 55(1):147-52. PubMed ID: 19858405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
    Sharabi Y; Adler E; Shamis A; Nussinovitch N; Markovitz A; Grossman E
    Am J Hypertens; 2006 Jul; 19(7):750-5. PubMed ID: 16814132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).
    Krieger EM; Drager LF; Giorgi DMA; Pereira AC; Barreto-Filho JAS; Nogueira AR; Mill JG; Lotufo PA; Amodeo C; Batista MC; Bodanese LC; Carvalho ACC; Castro I; Chaves H; Costa EAS; Feitosa GS; Franco RJS; Fuchs FD; Guimarães AC; Jardim PC; Machado CA; Magalhães ME; Mion D; Nascimento RM; Nobre F; Nóbrega AC; Ribeiro ALP; Rodrigues-Sobrinho CR; Sanjuliani AF; Teixeira MDCB; Krieger JE;
    Hypertension; 2018 Apr; 71(4):681-690. PubMed ID: 29463627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.
    Vaclavik J; Sedlak R; Jarkovsky J; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):50-5. PubMed ID: 23128822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal safety outcomes of spironolactone in patients with resistant hypertension.
    Galceran I; Vázquez S; Durán X; Outón S; Pascual J; Oliveras A
    Nefrologia (Engl Ed); 2020; 40(4):414-420. PubMed ID: 31898989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative Efficacy of the Influence of Fixed Combinations of Antihypertensive Drugs That Block the Renin-Angiotensin-Aldosterone System, With Thiazide Diuretics on the Parameters of Ambulatory Blood Pressure Monitoring].
    Ostroumova OD; Garelik IA
    Kardiologiia; 2016 Dec; 56(12):20-26. PubMed ID: 28290800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled treatment of primary hypertension with propranolol and spironolactone. A crossover study with special reference to initial plasma renin activity.
    Karlberg BE; Kågedal B; Tegler L; Tolagen K; Bergman B
    Am J Cardiol; 1976 Mar; 37(4):642-9. PubMed ID: 769527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population.
    Djoumessi RN; Noubiap JJ; Kaze FF; Essouma M; Menanga AP; Kengne AP; Mbanya JC; Sobngwi E
    BMC Res Notes; 2016 Mar; 9():187. PubMed ID: 27007793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.
    Vaclavik J; Sedlak R; Plachy M; Navratil K; Plasek J; Husar R; Kocianova E; Taborsky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):143-8. PubMed ID: 21804623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.